May 1, 2025 10:55 AM EDT
Pharma
FDA+

FDA ap­proves Sat­suma's mi­graine nasal spray af­ter re­jec­tion in 2024

Max Gelman

Senior Editor

The FDA ap­proved a new nasal spray for mi­graines that was de­vel­oped by Sat­suma Phar­ma­ceu­ti­cals.

Pre­vi­ous­ly called STS101, the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

FDA asks Covid vac­cine mak­ers to add more my­ocardi­tis da­ta to la­bels

Hinge Health is go­ing pub­lic on Thurs­day at a $3B val­u­a­tion

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Up­dat­ed: Eikon Ther­a­peu­tics cuts staff for the sec­ond time in less than two years

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times